YUMA THERAPEUTICS AWARDED A RESEARCH GRANT BY THE ALZHEIMER’S DRUG DISCOVERY FOUNDATION TO DEVELOP NOVEL THERAPEUTICS FOR ALZHEIMER’S DISEASE

March 28, 2011 – The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer’s disease.
The award will fund work to develop Yuma’s innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer’s disease... [PDF] Alzheimer’s Drug Discovery Foundation's Press Release -

Axxam : Research Grant by the Alzheimer’s Drug Discovery Foundation to develop Novel Therapeutics for Alzheimer’s Disease

June, 22nd 2011 - Axxam awarded a Research Grant by the Alzheimer’s Drug Discovery Foundation to develop Novel Therapeutics for Alzheimer’s Disease
The Alzheimer’s Drug Discovery Foundation (ADDF) and Axxam SpA entered a collaboration to develop small molecules to treat Alzheimer’s disease by targeting inflammation.
Under the terms of this agreement, Axxam will screen its extensive chemical library to identify compounds that block the puringeric receptor, P2X7, which is involved in inflammation in the brain.
One of the characteristic features of Alzheimer’s disease is a robust inflammatory response involving over-activation of specialized brain cells called microglia and the release of pro-inflammatory signals associated with the deposition of Alzheimer’s disease plaques in the brain. These pro-inflammatory signals are closely associated with the P2X7 receptor, putting this novel target at the heart of brain inflammation.
Compounds that block P2X7 may treat brain inflammation and can potentially be useful in the treatment of Alzheimer’s disease and other neurodegenerative diseases... [PDF] Axxam's Press Release -

Clarimedix : Treatment Targets Alzheimer's Symptoms with Non-Invasive, Non-Drug Device

March 7, 2011 - Clarimedix presents non-drug, non-invasive technology findings at International AD/PD Conference - Clarimedix Inc., ...results of recently completed animal studies on its groundbreaking, non-invasive treatment of Alzheimer's disease at the International Conference of the AD/PD (Alzheimer's Disease/Parkinson's Disease) Conference in Barcelona on March 9.
"We will describe how our technology is paving the way for what we believe will make Alzheimer's a controllable and treatable disease," says John Dunning, CEO and president of Clarimedix. "This has the potential to revolutionize Alzheimer's treatment options for patients and families."
The Clarimedix technology is a light-based medical device in the form of a flexible patch that is applied to the skin over the carotid artery. Using a proprietary wavelength and duration of light developed by Clarimedix, the device emits light through the skin and tissue down to the carotid artery. It then triggers targeted, localized and controllable production of nitric oxide, a well-known vasodilator and neurotransmitter capable of increasing blood flow, reducing inflammation and triggering gene expression changes in the brain...Clarimedix : recent news -

Mylan : Approval for Generic Version of Aricept® Tablets

June 7, 2011 - Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept® Tablets, which are used to treat dementia associated with Alzheimer's disease.

Donepezil HCl Tablets had U.S. sales of approximately $2.3 billion for the 12 months ending March 31, 2011, according to IMS Health. Mylan Pharmaceuticals Inc. is launching this product immediately.



Currently, Mylan has 164 ANDAs pending FDA approval representing $95.6 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health... Mylan's Press Release -